Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease.

IF 1.3 Q4 RHEUMATOLOGY European journal of rheumatology Pub Date : 2023-07-01 DOI:10.5152/eurjrheum.2023.22086
Adegbenga Bankole, Emma L Greear
{"title":"Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease.","authors":"Adegbenga Bankole,&nbsp;Emma L Greear","doi":"10.5152/eurjrheum.2023.22086","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and oth- ers for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporosis and an increase in the risk of fractures. The increased risk is related to both the daily dose and the cumulative dose of the glucocorticoids. Despite the availability of effective preventative and treatment options, glucocorticoid-induced osteoporosis is often not mitigated with the use of these preventive therapies. The risk of glucocorticoid-induced osteoporosis often also goes under- recognized, because it occurs in a different group of patients compared to age-related osteoporosis. As a result, glucocorticoid-induced osteoporosis is not always treated until after fractures may have occurred. Our objective is to determine if a structured health-care provider's educational interven- tion with intermittent educational updates would lead to improvement in the identification, evalu- ation, and prevention of glucocorticoid-induced osteoporosisin those patients at the highest risk of glucocorticoid-induced osteoporosis.</p><p><strong>Methods: </strong>In this single-center, prospective study, patients over 40 years of age, receiving a total cumu- lative dose of glucocorticoids of >5 g or a single dose of >30 mg of prednisone or its equivalent was enrolled. All providers attended an academic Journal Club, where the current American College of Rheumatology guidelines regarding glucocorticoid-induced osteoporosiswas reviewed. All providers received monthly reminders during academic meetings within the department.</p><p><strong>Results: </strong>There was a statistically significant improvement between pre- and post-educational data, with increasing use of glucocorticoid-induced osteoporosis preventive measures, which was sus- tained over the 12-month duration of the study.</p><p><strong>Conclusion: </strong>This research shows the importance of provider education as a means of disseminating information and improving the quality of patient care.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"97-100"},"PeriodicalIF":1.3000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/d1/ejr-10-3-97.PMC10543380.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/eurjrheum.2023.22086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and oth- ers for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporosis and an increase in the risk of fractures. The increased risk is related to both the daily dose and the cumulative dose of the glucocorticoids. Despite the availability of effective preventative and treatment options, glucocorticoid-induced osteoporosis is often not mitigated with the use of these preventive therapies. The risk of glucocorticoid-induced osteoporosis often also goes under- recognized, because it occurs in a different group of patients compared to age-related osteoporosis. As a result, glucocorticoid-induced osteoporosis is not always treated until after fractures may have occurred. Our objective is to determine if a structured health-care provider's educational interven- tion with intermittent educational updates would lead to improvement in the identification, evalu- ation, and prevention of glucocorticoid-induced osteoporosisin those patients at the highest risk of glucocorticoid-induced osteoporosis.

Methods: In this single-center, prospective study, patients over 40 years of age, receiving a total cumu- lative dose of glucocorticoids of >5 g or a single dose of >30 mg of prednisone or its equivalent was enrolled. All providers attended an academic Journal Club, where the current American College of Rheumatology guidelines regarding glucocorticoid-induced osteoporosiswas reviewed. All providers received monthly reminders during academic meetings within the department.

Results: There was a statistically significant improvement between pre- and post-educational data, with increasing use of glucocorticoid-induced osteoporosis preventive measures, which was sus- tained over the 12-month duration of the study.

Conclusion: This research shows the importance of provider education as a means of disseminating information and improving the quality of patient care.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
糖皮质激素诱导的骨质疏松症:提高对系统性自身免疫性风湿病患者预防该并发症的认识。
背景:据估计,约1%的美国人口接受长期糖皮质激素治疗。高剂量的糖皮质激素,特别是风湿病学家和其他治疗系统性自身免疫性风湿病的人使用的糖皮质素,会导致骨质流失,导致糖皮质激素诱导的骨质疏松症和骨折风险增加。风险增加与糖皮质激素的每日剂量和累积剂量有关。尽管有有效的预防和治疗选择,但糖皮质激素诱导的骨质疏松症往往不能通过使用这些预防性疗法来缓解。糖皮质激素引起的骨质疏松症的风险也经常被低估,因为与年龄相关的骨质疏松相比,它发生在不同的患者群体中。因此,糖皮质激素诱导的骨质疏松症并不总是在骨折发生后才能得到治疗。我们的目标是确定结构化医疗保健提供者的教育干预和间歇性的教育更新是否会改善糖皮质激素诱导的骨质疏松症高危患者的糖皮质激素诱发的骨质疏松的识别、评估和预防。方法:在这项单中心前瞻性研究中,纳入了40岁以上的患者,他们接受了总累积剂量>5 g的糖皮质激素或单剂量>30 mg的泼尼松或其等效物。所有提供者都参加了一个学术期刊俱乐部,在那里对目前美国风湿病学会关于糖皮质激素诱导的骨质疏松症的指南进行了审查。所有提供者在系内的学术会议期间每月都会收到提醒。结果:在研究的12个月内,随着糖皮质激素诱导的骨质疏松症预防措施的使用增加,教育前和教育后的数据之间有统计学上的显著改善。结论:本研究表明了提供者教育作为传播信息和提高患者护理质量的手段的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
56
审稿时长
7 weeks
期刊最新文献
Clinical and Serological Findings of Patients with Antiphospholipid Syndrome in Mashhad, Iran, from 2008 to 2018: A Retrospective, Descriptive, Cross-sectional Study. Diagnosis of Mental Disorders Complicated by Rheumatoid Arthritis: A Study of the Validity of a Questionnaire Method and Diagnosis by the Psychiatrist. Florid Reactive Periostitis of the Toe. Salt and Pepper Parotid Changes in Sjögren's Syndrome. The COVID-19 Pandemic Heightens Interest in Cytokine Storm Disease and Advances in Machine Learning Diagnosis, Telemedicine, and Primordial Prevention of Rheumatic Diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1